We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ionis (IONS) Offers Positive Interim Data on Lipid Candidate
Read MoreHide Full Article
Ionis Pharmaceuticals, Inc.’s (IONS - Free Report) wholly owned subsidiary, Akcea Therapeutics, announced positive data from an interim analysis of a phase I/IIa study on its pipeline candidate, IONIS-ANGPTL3-L RX. Data were presented at the American Heart Association Meeting.
In the study, patients who received multiple doses of ANGPTL3-L RX (10 mg, 20 mg, 40 mg and 60 mg) experienced dose-dependent and statistically significant mean reduction of up to 83%, 66% and 35% in angiopoietin-like 3, triglycerides and LDL-cholesterol, respectively.
The candidate demonstrated a favorable safety and tolerability profile with neither any discontinuation due to adverse events nor a clinically meaningful decline in platelets.
The encouraging study results support the development of IONIS-ANGPTL3-L RX for the treatment of multiple diseases such as severe dyslipidemias and nonalcoholic steatohepatitis.
We note that IONIS-ANGPTL3-L RX is being developed utilizing LIgand Conjugated Antisense (LICA) technology.
Ionis has a deep pipeline with several candidates in the mid or final stages of development. The most advanced candidate in the company’s pipeline is Spinraza, which is currently under review in the both the U.S. and the EU for the treatment of patients with spinal muscular atrophy. Other promising candidates include IONIS-TTRRx (phase III – transthyretin amyloidosis) and volanesorsen (phase III – familial chylomicronemia syndrome and familial partial lipodystrophy) among others.
Incyte’s earnings estimates increased from 20 cents to 68 cents for 2016 and from $1.42 to $1.69 for 2017 over the last 60 days. The company posted a positive average beat of 431.43% over the last four quarters.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 33.14%. Its share price has gained 15.1% year to date.
Exelixis’ loss estimates narrowed from 65 cents to 51 cents for 2016 and from a loss of 7 cents to earnings of 4 cents for 2017 over the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 38.52%. Its share price has skyrocketed above 150% year to date.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Ionis (IONS) Offers Positive Interim Data on Lipid Candidate
Ionis Pharmaceuticals, Inc.’s (IONS - Free Report) wholly owned subsidiary, Akcea Therapeutics, announced positive data from an interim analysis of a phase I/IIa study on its pipeline candidate, IONIS-ANGPTL3-L RX. Data were presented at the American Heart Association Meeting.
In the study, patients who received multiple doses of ANGPTL3-L RX (10 mg, 20 mg, 40 mg and 60 mg) experienced dose-dependent and statistically significant mean reduction of up to 83%, 66% and 35% in angiopoietin-like 3, triglycerides and LDL-cholesterol, respectively.
The candidate demonstrated a favorable safety and tolerability profile with neither any discontinuation due to adverse events nor a clinically meaningful decline in platelets.
The encouraging study results support the development of IONIS-ANGPTL3-L RX for the treatment of multiple diseases such as severe dyslipidemias and nonalcoholic steatohepatitis.
We note that IONIS-ANGPTL3-L RX is being developed utilizing LIgand Conjugated Antisense (LICA) technology.
Ionis has a deep pipeline with several candidates in the mid or final stages of development. The most advanced candidate in the company’s pipeline is Spinraza, which is currently under review in the both the U.S. and the EU for the treatment of patients with spinal muscular atrophy. Other promising candidates include IONIS-TTRRx (phase III – transthyretin amyloidosis) and volanesorsen (phase III – familial chylomicronemia syndrome and familial partial lipodystrophy) among others.
Ionis currently carries a Zacks Rank #3 (Hold).
IONIS PHARMACT Price
IONIS PHARMACT Price | IONIS PHARMACT Quote
Stocks to Consider
A few better-ranked stocks in the healthcare sector include Incyte Corporation (INCY - Free Report) , Anika Therapeutics (ANIK - Free Report) and Exelixis, Inc. (EXEL - Free Report) . Anika sports a Zacks Rank #1 (Strong Buy), while Incyte and Exelixis carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Incyte’s earnings estimates increased from 20 cents to 68 cents for 2016 and from $1.42 to $1.69 for 2017 over the last 60 days. The company posted a positive average beat of 431.43% over the last four quarters.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 33.14%. Its share price has gained 15.1% year to date.
Exelixis’ loss estimates narrowed from 65 cents to 51 cents for 2016 and from a loss of 7 cents to earnings of 4 cents for 2017 over the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 38.52%. Its share price has skyrocketed above 150% year to date.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>